HIV vaccine candidates

Drugs of Today

Volumn 40, Issue 11, 2004, Pages 949-955

  Wu, Tai Te ^a,c   Johnson, George ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b Northwestern University   (United States)

^c Technological Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; GLYCOPROTEIN GP 120; VIRUS PROTEIN; VIRUS VACCINE;

AMINO ACID SEQUENCE; ANTIBODY PRODUCTION; CRYSTALLIZATION; DISULFIDE BOND; DNA DETERMINATION; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; PEPTIDE ANALYSIS; PROTEIN STRUCTURE; REVIEW; THREE DIMENSIONAL IMAGING; TIME; VACCINATION; VIRUS GENE; VIRUS ISOLATION;

AIDS VACCINES; AMINO ACID SEQUENCE; ANTIBODIES, VIRAL; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HUMANS; MODELS, MOLECULAR;

EID: 11844287509     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2004.40.11.872583     Document Type: Review

References (29)

1. Hymes, K.B., Cheung, T., Greene, J.B. et al. Kaposi's sarcoma in homosexual men - A report of eight cases. Lancet 1981, 2 (8247): 598-600.
2. Gottlieb, M.S., Schroff, R., Schanker, H.M. et al. Pneumocystis carnii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence of a new acquired cellular immunodeficiency. New Eng J Med 1981, 305: 1425-31.
3. Zakowski, P., Fligiel, S., Borlin, G.W., Johnson, L. Jr. Disseminated Mycobacterium avium-intracellulare infection in homosexual men dying of acquired immunodeficiency. JAMA 1982, 248: 2980-2.
4. Quagliarello, V. The acquired immunodeficiency syndrome: Current status. Yale J Biol Med 1982, 55: 443-52.
5. Hinuma, Y., Nagata, K., Hanaoka, M. et al. Adult T-cell leukemia: Antigen in an ATL cell line and detection of antibodies to the antigen of human sera. Proc Natl Acad Sci USA 1981, 78: 6476-80.
6. Miyoshi, I., Kubonishi, I., Yoshimoto, S. et al. Type C virus particle in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukemic T cell. Nature 1981, 284: 770-1.
7. Chermann, J.C., Barre-Sinoussi, F., Dauguet, C. et al. Isolation of a new retrovirus in a patient at risk for acquired immunodeficiency syndrome. Antibiot Chemother 1983, 32: 48-53.
8. Barre-Sinoussi, F., Chermann, J.C., Rey, F. et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immunodeficiency syndrome (AIDS). Science 1983, 220: 868-71.
9. Levy, J.A. HIV and Pathogenesis of AIDS, 2nd ed. ASM Press: Washington 1998.
10. Frankel, A.D., Young, J.A.T. HIV-1: Fifteen proteins and an RNA. Ann Rev Biochem 1998, 67: 1-25.
11. Janssens, W., Nkengasong, J., Heyndrickx, L. et al. Intrapatient variability of HIV type I group O ANT70 during a 10-yearyollow-up. AIDS Res Hum Retroviruses 1999, 15: 1325-32.
12. Johnson, G., Wu, T.T. The Kabat database and a bioinformatics example. In: Antibody Engineering: Methods and Protocols. B.K.C. Lo (Ed.). Humana Press: Totowa 2003, Chapter 2.
13. Wyatt, R., Kwong, P.D., Desjardina, E. et al. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998, 393: 705-11.
14. Wu, T.T., Kabat, E.A. An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J Exp Med 1970, 132: 211-50.
15. Yamaguchi-Kabata, Y., Gojobori, T. Reevaluation of amino acid variability of the human immunodeficiency virus type 1 gp120 envelope glycoprotein and prediction of their discontinuous epitopes. J Virol 2000, 74: 4335-50.
16. Bhana, N., Ormrod, D., Perry, C.M., Figgitt, D.P. Zidovudine: A review of its use in the management of vertically-acquired pediatric HIV infection. Paediatr Drugs 2002, 4: 515-53.
17. Corbett, J.W., Rodgers, J.D. Discovery of second generation quinazolinone non-nucleotide reverse transcriptase inhibitors of HIV-1. Prog Med Chem 2002, 40: 63-105.
18. Smith, A.M. III, Cantin, L.D., Pasternak, A. et al. Design, synthesis and biological evaluation of monopyrrolinone-based HIV-1 protease inhibitors. J Med Chem 2003, 46: 1831-1844.
19. Kilby, J.M., Lalezari, J.P., Eron, J.J. et al. The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous enfuvirtide (T-20), a peptide inhibitor of gp41-mediated virus fusion, in HIV-infected adults. AIDS Res Hum Retroviruses 2002, 18: 685-93.
20. Reiher, W.E. III, Blalock, J.E., Brunck, T.K. Sequence homology between acquired immunodeficiency syndrome virus envelope protein and interleukin 2. Proc Natl Acad Sci USA 1986, 83: 9188-92.
21. Takahashi, H., Cohen, J., Hosmalin, A. et al. An immunodominant epitope of the HIV gp160 envelope glycoprotein recognized by class I MHC molecule-restricted murine cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1988, 85: 3105-9.
22. Defoort, J.-P., Nardelli, B., Huang, W., Ho, D.D., Tam, J.P. Macromolecular assemblage in the design of a synthetic AIDS vaccine. Proc Natl Acad Sci USA 1992, 89: 3879-83.
23. Kozlowski, S., Corr, M., Takeshita, T. et al. Serum angiotensin-1 converting enzyme activity processes a human immunodeficiency virus I gp160 peptide for presentation by major histocomapatibility complex class I molecules. J Exp Med 1992, 175: 1417-22.
24. Ahlers, J.D., Takeshita, T., Pendleton, C.D., Berzofzky, J.A. Enhanced immunogenicity of HIV-1 vaccine construct by modification of the native peptide sequence. Proc Natl Acad Sci USA 1997, 94: 10856-61.
25. Carlos, M.P., Anderson, D.E., Gardner, M.B., Torres, J.V. Immunogenicity of a vaccine preparation representing the variable regions of the HIV type I envelope glycoprotein. AIDS Res Hum Retroviruses 2000, 16: 153-61.
26. Xiao, Y., Zhao, Y., Lu, Y., Chen, Y.H. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibodies. Immunol Invest 2000, 29: 41-50.
27. Naylor, P.M., Naylor, C.W., Badamchian, M. et al. Human immunodeficiency virus contains an epitope immunoreactive with thymosin alpha 1 and the 30-amino acid synthetic p17 group-specific antigen peptide HGP-30. Proc Natl Acad Sci USA 1987, 84: 2951-5.
28. Nishino, Y., Kameoka, M., Okada, Y. et al. In vivo induction of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes and delay-type hypersensitivity by a 23-amino acid peptide from the highly conserved region of major core protein p24. Vaccine 1994, 12: 485-91.
29. Okuda, K., Kaneko, T., Yamakawa, T. et al. Strong immunogenicity of a multicomponent peptide vaccine developed with the branched lysine oligopeptide method for human immunodeficiency virus infection. J Mol Recognit 1993, 6: 101-9.